Vanda Pharmaceuticals (VNDA) Revenue (2010 - 2026)

Vanda Pharmaceuticals has reported Revenue for 17 years, with the latest figure at $51.7 million in Q1 2026.

• Quarterly Revenue rose 3.35% year-over-year to $51.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $217.8 million (up 8.16% YoY) and the FY2025 annual result came in at $216.1 million, up 8.72% from the prior year.
• Revenue retreated to $51.7 million in Q1 2026 per VNDA's latest filing, from $57.2 million in the prior quarter.
• Over five years, Revenue peaked at $65.3 million in Q3 2022 and troughed at $38.8 million in Q3 2023.
• A 5-year average of $53.7 million and a median of $52.6 million in 2025 frame the typical range for Revenue.
• The sharpest annual moves came in 2023 and 2024: Revenue slumped 40.58% in 2023, then grew 22.76% in 2024.
• Over 5 years, Revenue stood at $64.5 million in 2022, then declined by 29.79% to $45.3 million in 2023, then rose by 17.48% to $53.2 million in 2024, then climbed by 7.58% to $57.2 million in 2025, then slipped by 9.61% to $51.7 million in 2026.
• According to Business Quant data, Revenue over the past three periods registered $51.7 million, $57.2 million, and $56.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.